Thoracic and abdominal aortic aneurysms are multifactorial conditions with a significant genetic component. Currently, there are approximately 30 genes associated with thoracic aortic aneurysms (TAA) and 24 genetic loci associated with abdominal aortic aneurysms (AAA). Recent studies have shown the importance of utilizing genetic testing in the management of aortic aneurysms and the prevention of acute aortic syndromes. Genetic testing can be used as a tool to assess one’s future risk for aneurysmal growth or dissection, to guide medical management and surgical decisions, and to assess risk for family members. Additionally, genetic testing has become more accessible and available to patients in that it can be ordered by most healthcare providers and is covered by most insurance plans. Recent guidelines have allowed for a better understanding of when to offer genetic testing and what risk factors to assess for. These advancements and increased accessibility to aortic aneurysm genetics have allowed for improved screening and treatment.